Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
Study Identifier:
C10-001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Nov 2011 - May 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Nov 2011 - May 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization therapy.
Trial Locations
Location
Status
Location
Birmingham, Alabama, United States, 35294
Status
N/A
Location
La Jolla, California, United States, 92037
Status
N/A
Location
Los Angeles, California, United States, 90095
Status
N/A
Location
San Francisco, California, United States, 94143
Status
N/A
Location
Washington, D.C., District of Columbia, United States, 20007
Status
N/A
Location
Atlanta, Georgia, United States, 30309
Status
N/A